Patent ID: 11865111
Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A  C

Claim 5:
6. A method for treatment of SARS-COV-1, SARS-CoV-2 (Covid-19) and MERS-CoV, and variants within each, in a mammalian subject in need thereof, comprising administering to the subject an effective amount of the following piperdine compounds selected from the group consisting of:
1-(3-ethoxy-4-hydroxybenzyl)-N-(3′-fluoro-[1,1′-biphenyl]-3-yl)piperidine-4-carboxamide;
1-(3-ethoxy-4-hydroxybenzyl)-N-(3′-(trifluoromethyl)-[1,1′-biphenyl]-3-yl)piperidine-4-carboxamide;
1-(3-ethoxy-4-hydroxybenzyl)-N-(3′-methoxy-[1,1′-biphenyl]-3-yl)piperidine-4-carboxamide;
N-(3′-chloro-[1,1′-biphenyl]-3-yl)-1-(3-hydroxy-4-methoxybenzyl)piperidine-4-carboxamide;
N-(3′-chloro-[1,1′-biphenyl]-3-yl)-1-(3-ethoxy-4-hydroxybenzyl)piperidine-4-carboxamide; or
N-(4′-chloro-[1,1′-biphenyl]-3-yl)-1-(3-ethoxy-4-hydroxybenzyl)piperidine-4-carboxamide.